Source: CentralCharts

Press Release: Leap Therapeutics : Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Securities

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an underwritten public offering of 6,571,428 shares of its common stock and warrants to purchase up to 6,571,428 shares of its common stock,

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Chris Mirabelli's photo - CEO of Leap Therapeutics

CEO

Chris Mirabelli

CEO Approval Rating

73/100

Leap Therapeutics researches, develops and commercializes monoclonal antibodies that enable immune system to identify and attack cancer cells. Read more